Dapagliflozin to prevent atrial fibrillation coming back after cardioversion

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase 3 study enrolls adults aged 55 and older with atrial fibrillation who are scheduled for electrical cardioversion and assigns them to dapagliflozin 10 mg once daily or to usual care. Participants take the study drug (or no drug) for up to 56 days, undergo the planned cardioversion, and record their heart rhythm with a hand-held ECG device that transmits data to the investigators. The main outcome is recurrence of atrial fibrillation during the 56-day monitoring period. The trial is conducted at multiple academic hospitals in Sweden and excludes patients with prior heart failure, type 1 diabetes, current SGLT2 inhibitor use, recent or planned pulmonary vein isolation, or severe kidney impairment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date.
* Age ≥ 55 years.
* Provided written informed consent.

Exclusion Criteria:

* Current treatment with an SGLT2 inhibitor.
* Prior/current diagnosis of heart failure.
* Type 1 diabetes mellitus.
* Estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m2.
* Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days).
* Contraindications to SGLT2 inhibitors.
* Any condition or circumstance in which the patient should not participate in the study according to the study investigator.

Where it's running

• Örebro University hospital
  Örebro, Sweden Recruiting
• Karolinska University Hospital
  Stockholm, Sweden Recruiting
• Linköping university hosptial
  Linköping, Sweden Not yet recruiting
• Södersjukhuset
  Stockholm, Sweden Not yet recruiting
• Danderyds Hospital
  Stockholm, Sweden Not yet recruiting
• Norrlands universitetssjukhus
  Umeå, Sweden Not yet recruiting

Study contacts

• Principal investigator: Karolina Szummer, MD PhD — Karolinska Institutet
• Study coordinator: Karolina Szummer, MD PhD
• Email: karolina.szummer@regionstockholm.se
• Phone: +4681238000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation

  This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.

  Recruiting St. Josefs-Hospital Wiesbaden GmbH · Wiesbaden · NCT07910370

• Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation

  This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.

  Recruiting East Sussex Healthcare NHS Trust · Eastbourne · NCT07900685

• Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF

  This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.

  Recruiting Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07874763

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes

  This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.

  Recruiting at 5 sites Insel Gruppe AG, University Hospital Bern · Zabrze and 4 other locations · NCT07852221

• AI-based cardiac analysis using 12-lead and 1-lead ECG

  A clinician-facing pilot test to see if SmartECG-EF helps evaluate heart function using both 12-lead and single-lead ECGs in adults with heart conditions.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07844434

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.